Cardiome Pharma Corp. Announces Voting Results

                Cardiome Pharma Corp. Announces Voting Results

PR Newswire

VANCOUVER, July 2, 2013


VANCOUVER, July 2, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) today announced the results of voting at its 2013 Annual General and
Special Meeting of Shareholders held on June 28, 2013.

A total of 7,995,664 common shares were voted in connection with the meeting,
representing approximately 64.12% of the issued and outstanding common shares
of the company. Shareholders voted as follows:

Appointment of Auditor

By resolution passed by show of hands, KMPG LLP, Chartered Accountants, was
appointed auditor of the company for the ensuing year.

Election of Directors

By resolution passed by ballot vote, the following five nominees proposed by
management were elected as directors of Cardiome to hold office until the next
annual meeting of Shareholders or until their successors are elected or

Nominee             Votes For % Votes For Votes Withheld % Votes Withheld
Robert W. Rieder    4,859,925    99.18        40,088           0.82
Peter W. Roberts    4,857,052    99.12        42,961           0.88
Harold H. Shlevin   4,813,131    98.23        86,882           1.77
Richard M. Glickman 4,856,952    99.12        43,061           0.88
William L. Hunter   4,860,562    99.19        39,451           0.81

Renewal of Stock Option Plan

By resolution passed by show of hands, the Cardiome's Stock Option Plan was
ratified, confirmed and re-approved, all unallocated options under the Stock
Option Plan were approved, and the Company was granted the ability to continue
granting options under the Stock Option Plan until June 28, 2016.

Adoption of Advance Notice Bylaw

By resolution passed by show of hands, an amendment to the company's by-laws
was approved to adopt provisions regarding advanced notice for director
nominations (the "Advance Notice Bylaw") as outlined in the company's
management information circular.

The purpose of the Advance Notice Bylaw is to provide shareholders, directors
and management of Cardiome with direction on the procedure for shareholder
nomination of directors. The Advance Notice Bylaw is the framework by which
the company seeks to fix a deadline by which registered or beneficial holders
of common shares of the company must submit director nominations to the
company prior to any annual or special meeting of shareholders and sets forth
the information that a shareholder must include in the notice to the company
for the notice to be in proper written form. No person will be eligible for
election as a director of the company unless nominated in accordance with the
provisions of the Advance Notice Bylaw.

In the case of an annual meeting of shareholders, notice to the company must
be made not less than 30 days and not more than 60 days prior to the date of
the annual meeting; provided, however, that in the event that the annual
meeting is to be held on a date that is less than 60 days after the date on
which the first public announcement of the date of the annual meeting was
made, notice may be made not later than the close of business on the 10th day
following such public announcement.

In the case of a special meeting of shareholders (which is not also an annual
meeting), notice to the company must be made not later than the close of
business on the 10th day following the day on which the first public
announcement of the date of the special meeting was made.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one marketed
product, BRINAVESS™ (vernakalant IV), approved in Europe and other territories
for the rapid conversion of recent onset atrial fibrillation to sinus rhythm
in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock
Exchange (COM). For more information, please visit our web site at

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions.
Forward- looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our financial
condition and the results of, or outlook for, our operations, research and
development and product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions in the United States, Canada, Europe, and the
other regions in which we operate; market demand; technological changes that
could impact our existing products or our ability to develop and commercialize
future products; competition; existing governmental legislation and
regulations and changes in, or the failure to comply with, governmental
legislation and regulations; availability of financial reimbursement coverage
from governmental and third-party payers for products and related treatments;
adverse results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety and/or efficacy
of our products or products; decisions, and the timing of decisions, made by
health regulatory agencies regarding approval of our technology and products;
the requirement for substantial funding to expand commercialization
activities; and any other factors that may affect our performance. In
addition, our business is subject to certain operating risks that may cause
any results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified personnel; our
ability to successfully complete pre-clinical and clinical development of our
products; changes in our business strategy or development plans; intellectual
property matters, including the unenforceability or loss of patent protection
resulting from third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture, market and
sell our products; the availability of capital to finance our activities; and
any other factors described in detail in our filings with the Securities and
Exchange Commission available at and the Canadian securities
regulatory authorities at Given these risks, uncertainties and
factors, you are cautioned not to place undue reliance on such forward-looking
statements and information, which are qualified in their entirety by this
cautionary statement. All forward-looking statements and information made
herein are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to reflect
subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.


Cardiome Investor Relations
(604) 676-6993 or Toll Free: 1-800-330-9928
Press spacebar to pause and continue. Press esc to stop.